EssilorLuxottica yesterday released the much-anticipated three-year clinical trial results of its breakthrough innovation Essilor Stellest lens, for the first time at the International Myopia Conference (IMC) 2022 in Rotterdam, Netherlands. The results show that the Essilor Stellest lenses continue to exhibit strong efficacy in slowing myopia progression and axial elongation in the third year of the clinical trial.
EssilorLuxottica’s partnership with IMC as a diamond sponsor this year continues to demonstrate the Group’s commitment to sharing insights and expertise on myopia control globally and providing innovative solutions for children to help slow down their myopia progression.
EssilorLuxottica’s satellite session was facilitated by Dr. Mark A. Bullimore, MCOptom, PhD, FAAO – University of Houston, College of Optometry Professor, and Olga Prenat, Head, Medical Marketing, Professional Relations and Vision Care Education, EssilorLuxottica. The session titled ‘Essilor Stellest lens – New benefits of myopia control spectacle lenses’ saw presentations from EssilorLuxottica’s research and development experts, Dr. Damien Paillé and Dr. Björn Drobe. The session also had presentations from Dr. Padmaja Sankaridurg, BOptom, MIP, PhD, Head, Myopia Program, Brien Holden Vision Institute, titled ‘Essilor Stellest lens: Results from a randomised, double-blind, cross-over clinical trial’ and from Dr. Bullimore on the impact of spectacle lenses for myopia control on visual function, and myopia control in other ethnicities. There was also a plenary talk by Dr. Drobe titled ‘Myopia control efficacy of spectacle lenses with highly aspherical lenslets: three-year results’.